145th ENMC International Workshop: Planning for an International Trial of Steroid Dosage Regimes in DMD (FOR DMD) 22-24th October 2006, Naarden, The Netherlands

Neuromuscular Disorders

Volumn 17, Issue 5, 2007, Pages 423-428

  Bushby, K ^a   Griggs, R ^b  

^a INSTITUTE OF HUMAN GENETICS   (United Kingdom)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; DEFLAZACORT; MYOSTATIN; PREDNISONE; UTROPHIN;

ANTISENSE THERAPY; ARTICLE; CLINICAL TRIAL; DRUG DOSE REGIMEN; DUCHENNE MUSCULAR DYSTROPHY; GENE REPRESSION; GENE THERAPY; HUMAN; PHYSIOTHERAPY; PRIORITY JOURNAL; SCOLIOSIS; STEM CELL TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; VERTEBRA FRACTURE; VIRAL GENE THERAPY;

CLINICAL TRIALS; HUMANS; INTERNATIONAL COOPERATION; MUSCULAR DYSTROPHY, DUCHENNE; NETHERLANDS; RESEARCH DESIGN; STEROIDS;

EID: 34247584629     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2007.01.006     Document Type: Article

References (31)

1. Bushby K, Muntoni F, et al. (2004). Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the uses of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromusc Disord 14(8-9):526-34.
2. Manzur A.Y., Kuntzer T., et al. Glucocorticoid corticosteroids for Duchenne muscular dystrophy. Cochrane Database Syst Rev 2 (2004) CD003725
3. Moxley R.T., Ashwal S., et al. Corticosteroid treatment of Duchenne dystrophy [Report of the Quality standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society]. Neurology 64 1 (2005) 13-20
4. Silversides C.K., Webb G.D., et al. Effects of deflazacort on left ventricular function in patients with Duchenne muscular dystrophy. Am J Cardiol 91 6 (2003) 769-772
5. Biggar W.D., Politano L., et al. Deflazacort in Duchenne muscular dystrophy: a comparison of two different protocols. Neuromuscul Disord 14 8-9 (2004) 476-482
6. Biggar W.D., Harris V.A., et al. Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16 4 (2006) 249-255
7. Braun S. Naked plasmid DNA for the treatment of muscular dystrophy. Curr Opin Mol Ther 6 5 (2004) 499-505
8. Goyenvalle A., Vulin A., et al. Rescue of dystrophic muscle through U7 snRNA-mediated exon skipping. Science 306 5702 (2004) 1796-1799
9. Nelson R. Utrophin therapy for Duchenne muscular dystrophy?. Lancet Neurol 3 11 (2004) 637
10. Romero N.B., Braun S., et al. Phase I study of dystrophin plasmid-based gene therapy in Duchenne/Becker muscular dystrophy. Hum Gene Ther 15 11 (2004) 1065-1076
11. Fardeau M., Braun S., et al. [About a phase I gene therapy clinical trial with a full-length dystrophin gene-plasmid in Duchenne/Becker muscular dystrophy]. J Soc Biol 199 1 (2005) 29-32
12. Hirst R.C., McCullagh K.J., et al. Utrophin upregulation in Duchenne muscular dystrophy. Acta Myol 24 3 (2005) 209-216
13. Liu M., Yue Y., et al. Adeno-associated virus-mediated microdystrophin expression protects young mdx muscle from contraction-induced injury. Mol Ther 11 2 (2005) 245-256
14. Alter J., Lou F., et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 12 2 (2006) 175-177
15. Beroud C., Tuffery-Giraud S., et al. Multiexon skipping leading to an artificial DMD protein lacking amino acids from exons 45 through 55 could rescue up to 63% of patients with Duchenne muscular dystrophy. Hum Mutat (2006)
16. Fletcher S., Honeyman K., et al. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 8 2 (2006) 207-216
17. Gregorevic P., Allen J.M., et al. rAAV6-microdystrophin preserves muscle function and extends lifespan in severely dystrophic mice. Nat Med 12 7 (2006) 787-789
18. Hamed S.A. Drug evaluation: PTC-124 - a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs 9 11 (2006) 783-789
19. Miura P., and Jasmin B.J. Utrophin upregulation for treating Duchenne or Becker muscular dystrophy: how close are we?. Trends Mol Med 12 3 (2006) 122-129
20. Sampaolesi M., Blot S., et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature (2006)
21. Wilton S.D., and Fletcher S. Redirecting splicing to address dystrophin mutations: molecular by-pass surgery. Prog Mol Subcell Biol 44 (2006) 161-197
22. Bogdanovich S., Krag T.O., et al. Functional improvement of dystrophic muscle by myostatin blockade. Nature 420 6914 (2002) 418-421
23. Bogdanovich S., Perkins K.J., et al. Myostatin propeptide-mediated amelioration of dystrophic pathophysiology. FASEB J 19 6 (2005) 543-549
24. Whittemore L.A., Song K., et al. Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun 300 4 (2003) 965-971
25. Atkinson M.J., Sinah A., et al. Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease. Health Quality Life Outcomes 2 12 (2004)
26. Scott E., and Mawson S.J. Measurement in Duchenne muscular dystrophy: considerations in the development of a neuromuscular assessment tool. Dev Med Child Neurol 48 6 (2006) 540-544
27. Bianchi M.L., Mazzanti A., et al. Bone mineral density in Duchenne muscular dystrophy. Osteoporosis Int 14 (2003) 761-767
28. Biggar LK, Bachrach RC, et al. (2005). Bone health in Duchenne muscular dystrophy: a workshop report from the meeting in Cincinnati, Ohio, July 8, 2004. Neuromuscul Disord 15(1):80-5.
29. Quinlivan R., Roper H., et al. Report of a Muscular Dystrophy Campaign funded workshop Birmingham, UK, January 16th 2004. Osteoporosis in Duchenne muscular dystrophy; its prevalence, treatment and prevention. [see comment]. Neuromuscul Disord 15 1 (2005) 72-79
30. Bushby KMD, Muntoni F, et al. (2003). The management of cardiac complications in muscular dystrophy and myotonic dystrophy. In: Proceedings of 107th ENMC Workshop, Neuromuscul Disord, vol. 13. p. 166-172.
31. Finder J.D., Birnkrant D., et al. Respiratory care of the patient with Duchenne muscular dystrophy: ATS consensus statement. Am J Respir Crit Care Med 170 4 (2004) 456-465